Sensei Biotherapeutics (SNSE) has released an update.
The Board of Directors has decided to streamline its structure by reducing its members from nine to eight and has named Bill Ringo as the Interim Chair for the Nominating and Corporate Governance Committee, with both changes taking effect immediately. This move aims to enhance the board’s efficiency and oversight capabilities.
For further insights into SNSE stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
